Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aranesp Monthly Preference Study
NCT00117130Phase 4Completed
- Sponsor
- Amgen
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Phase 4, open-label, single-arm trial of darbepoetin alfa in anemia of chronic kidney disease (CKD-A), sponsored by Amgen. Primary endpoint: Subject preference for Aranesp QM vs Procrit QW at Week 21. Status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT00117130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117130.